Answer
The safety and efficacy of agalsidase beta (Fabrazyme) have not been established in patients older than 65 years, and no dosage regimen can presently be recommended for these patients.
Sources for this answer
- Fabrazyme 35mg powder for concentrate for solution for infusionSANOFI · emc · SmPC §4.2 Posology and method of administration · Version 2Document updated
Sources checked